Literature DB >> 1941364

Ambivalence toward methadone treatment among intravenous drug users.

A Rosenblum1, S Magura, H Joseph.   

Abstract

Interviews were conducted with a sample of jailed intravenous opioid users who were not in treatment at the time of their arrest and who were admitted to an in-jail methadone maintenance program. At release, subjects were to be referred to dedicated slots in participating community methadone programs. Virtually all subjects were daily injectors of heroin and cocaine. Although the majority of subjects had previous episodes of methadone maintenance, most reported anxieties about methadone, such as bone decalcification and possible overdosing. Women and subjects who shared needles were more likely to report fears about methadone. Only 52% of the subjects stated that they intended to report to a methadone program after their release and 45% did not expect to remain in treatment for more than one year. Subjects who stated that they were not afraid of methadone, frequently injected drugs, and rarely used crack were more likely to express intentions to enroll and remain in community methadone treatment. Ambivalence toward methadone treatment may be a result of unrealistic concerns about the side effects of methadone and personal heuristics regarding the nature of addiction and the efficacy of treatment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1941364     DOI: 10.1080/02791072.1991.10472571

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  18 in total

1.  Beliefs about methadone in an inner-city methadone clinic.

Authors:  Sharon Stancliff; Julie Elana Myers; Stuart Steiner; Ernest Drucker
Journal:  J Urban Health       Date:  2002-12       Impact factor: 3.671

2.  Cocaine and opioid use during pregnancy: prevalence and management.

Authors:  Chaya G Bhuvaneswar; Grace Chang; Lucy A Epstein; Theodore A Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

3.  Why don't out-of-treatment individuals enter methadone treatment programmes?

Authors:  James A Peterson; Robert P Schwartz; Shannon Gwin Mitchell; Heather Schacht Reisinger; Sharon M Kelly; Kevin E O'Grady; Barry S Brown; Michael H Agar
Journal:  Int J Drug Policy       Date:  2008-09-20

Review 4.  Mainstreaming methadone maintenance treatment: the role of the family physician.

Authors:  M Latowsky; E Kallen
Journal:  CMAJ       Date:  1997-08-15       Impact factor: 8.262

5.  Heroin-dependent inmates' experiences with buprenorphine or methadone maintenance.

Authors:  Ezechukwu Awgu; Stephen Magura; Andrew Rosenblum
Journal:  J Psychoactive Drugs       Date:  2010-09

6.  Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system.

Authors:  Jan Gryczynski; Jerome H Jaffe; Robert P Schwartz; Kristi A Dušek; Nishan Gugsa; Cristin L Monroe; Kevin E O'Grady; Yngvild K Olsen; Shannon Gwin Mitchell
Journal:  Am J Addict       Date:  2013 May-Jun

7.  Leaving buprenorphine treatment: patients' reasons for cessation of care.

Authors:  Jan Gryczynski; Shannon Gwin Mitchell; Jerome H Jaffe; Kevin E O'Grady; Yngvild K Olsen; Robert P Schwartz
Journal:  J Subst Abuse Treat       Date:  2013-10-14

8.  Incarceration and opioid withdrawal: the experiences of methadone patients and out-of-treatment heroin users.

Authors:  Shannon Gwin Mitchell; Sharon M Kelly; Barry S Brown; Heather Schacht Reisinger; James A Peterson; Adrienne Ruhf; Michael H Agar; Robert P Schwartz
Journal:  J Psychoactive Drugs       Date:  2009-06

9.  Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes.

Authors:  Harlan Matusow; Samuel L Dickman; Josiah D Rich; Chunki Fong; Dora M Dumont; Carolyn Hardin; Douglas Marlowe; Andrew Rosenblum
Journal:  J Subst Abuse Treat       Date:  2012-12-03

10.  Attitudes toward methadone among out-of-treatment minority injection drug users: implications for health disparities.

Authors:  Nickolas D Zaller; Alexander R Bazazi; Lavinia Velazquez; Josiah D Rich
Journal:  Int J Environ Res Public Health       Date:  2009-02-23       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.